Abstract Number: 2576 • ACR/ARP Annual Meeting 2019
Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors have demonstrated durable benefit in some cancer patients. However, checkpoint inhibitors are also associated with new onset autoimmune adverse events. …
ACR Meeting Abstracts